The attribution to Lonsurf does not appear to be accurate.
It is an interesting contention as Taiho Oncology's trifluridine/ tipiracil has considerable adverse side effects, modest OS improvements and is short lived compared with SRX's.
The FDA did approve Taiho's Lonsurf on Sep 22, 2015 however that approval on such a date does not allow for such considerable marketing by Taiho and the EMA only approved in the April of 2015 so that contention appears inconsistent with the facts and timelines required for such marketing by Taiho Oncology.
The takeup of such a drug with such adverse side effects produced by a Japanese biopharma is not to my mind compelling.
Ann: Investigation of Concerns around CEO Share Trading, page-48
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.003(1.41%) |
Mkt cap ! $75.62M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.8¢ | 17.5¢ | $4.968K | 28.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 5792335 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 265720 | 27 |
View Market Depth
| Last trade - 15.20pm 30/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |